Opinion Review
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2020; 26(24): 3318-3325
Published online Jun 28, 2020. doi: 10.3748/wjg.v26.i24.3318
Extended lymphadenectomy in hilar cholangiocarcinoma: What it will bring?
Jian Li, Meng-Hao Zhou, Wen-Jie Ma, Fu-Yu Li, Yi-Lei Deng
Jian Li, Meng-Hao Zhou, Yi-Lei Deng, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan Province, China
Wen-Jie Ma, Fu-Yu Li, Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Li J and Deng YL wrote the majority of the manuscript; Zhou MH, Ma WJ and Li FY collected all the materials and were also involved in editing the manuscript; Deng YL revised the manuscript critically and provided final approval of the version to be published.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Yi-Lei Deng, MD, Chief Doctor, Professor, Surgeon, Surgical Oncologist, Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University, No. 01 Jian She Road, Zhengzhou 450000, Henan Province, China. Dengyilei@163.com
Received: November 11, 2019
Peer-review started: November 19, 2019
First decision: April 1, 2020
Revised: May 11, 2020
Accepted: June 4, 2020
Article in press: June 4, 2020
Published online: June 28, 2020
Processing time: 220 Days and 21.4 Hours
Abstract

Lymph node dissection is always a hot issue in radical resection of hilar cholangiocarcinoma (HCCA). There are still controversies regarding whether some lymph nodes should be dissected, of which the para-aortic lymph nodes are the most controversial. This review synthesized findings in the literature using the PubMed database of articles in the English language published between 1990 and 2019 on the effectiveness of extended lymphadenectomy including para-aortic lymph nodes dissection in radical resection of HCCA. Hepatobiliary surgeons have basically achieved a consensus that enough lymph nodes should be obtained to accurately stage HCCA. Only a very small number of studies have focused on the effectiveness of extended lymphadenectomy including para-aortic nodes dissection on HCCA. They reported that extended lymphadenectomy can bring some survival benefits for patients with potential para-aortic lymph node metastasis and more lymph nodes can be obtained to make the patient's tumor staging more accurate without increasing the related complications. Extended lymphadenectomy should not be adopted for HCCA patients with intraoperatively confirmed distant lymph node metastases. For these patients, radical resection combined with postoperative adjuvant chemotherapy seems to be a better choice. A prospective, multicenter, randomized, controlled clinical study of regional lymphotomy and extended lymphadenectomy in HCCA should be conducted to guide clinical practice. A standardized extended lymphadenectomy may help to more accurately stage HCCA. Future studies are required to further assess whether extended lymphadenectomy can improve long-term survival in negative celiac, superior mesenteric, and para-aortic lymph node diseases.

Keywords: Hilar cholangiocarcinoma; Lymphadenectomy; Prognosis

Core tip: For patients with resectable hilar cholangiocarcinoma (HCCA), extended lymphadenectomy including the No.16 group may obtain more lymph nodes to more accurately stage the tumor and to reduce the influence of total lymph node count on the lymph node ratio when compared with single enlarged No.16 lymph node biopsy. In addition, it also may help to prevent the occurrence of lymph node micrometastases, which will avoid the difficult to determine cause of postoperative enlargement of the No.16 group lymph nodes. Therefore, extended lymphadenectomy including the No.16 group is potentially more consistent with the principle of lymph node dissection in radical resection of HCCA.